Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
SLGL
Upturn stock ratingUpturn stock rating

Sol Gel Technologies Ltd (SLGL)

Upturn stock ratingUpturn stock rating
$15.25
Last Close (24-hour delay)
Profit since last BUY87.58%
upturn advisory
Consider higher Upturn Star rating
BUY since 20 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: SLGL (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $4

1 Year Target Price $4

Analysts Price Target For last 52 week
$4 Target price
52w Low $4.01
Current$15.25
52w High $16.89

Analysis of Past Performance

Type Stock
Historic Profit -46.18%
Avg. Invested days 20
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 43.01M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 1
Beta 1.22
52 Weeks Range 4.01 - 16.89
Updated Date 08/15/2025
52 Weeks Range 4.01 - 16.89
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.7

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Earnings Date

Report Date 2025-08-14
When -
Estimate -0.67
Actual -

Profitability

Profit Margin -107.78%
Operating Margin (TTM) -879.63%

Management Effectiveness

Return on Assets (TTM) -26.82%
Return on Equity (TTM) -49.39%

Valuation

Trailing PE -
Forward PE 9.34
Enterprise Value 27289165
Price to Sales(TTM) 3.55
Enterprise Value 27289165
Price to Sales(TTM) 3.55
Enterprise Value to Revenue 2.25
Enterprise Value to EBITDA 0.24
Shares Outstanding 2785760
Shares Floating 689337
Shares Outstanding 2785760
Shares Floating 689337
Percent Insiders 70
Percent Institutions 15.75

ai summary icon Upturn AI SWOT

Sol Gel Technologies Ltd

stock logo

Company Overview

overview logo History and Background

Sol Gel Technologies Ltd. was founded in 1997 in Israel and went public on the Nasdaq in 2018. They specialize in developing and manufacturing microencapsulated active ingredients for use in various skincare and pharmaceutical products.

business area logo Core Business Areas

  • Dermatology: Development and commercialization of topical generic and branded dermatology products.
  • Active Ingredient Encapsulation: Developing and supplying microencapsulated active ingredients for cosmetic and pharmaceutical applications.

leadership logo Leadership and Structure

Dr. Alon Seri-Levy serves as the Chief Executive Officer. The company has a Board of Directors and operates with a functional organizational structure based on research, development, manufacturing, and commercial operations.

Top Products and Market Share

overview logo Key Offerings

  • EPSOLAYu00ae: A proprietary microencapsulated benzoyl peroxide (BPO) cream for the treatment of papulopustular rosacea. Market share is growing but still relatively small, competing with brands like Metrogel and Finacea. Revenue estimates not available, but important for growth and expansion.
  • ZELSUVMIu00ae: A topical antifungal medication using their encapsulation technology. Further expanding and diversifying their product portfolio. Competitors are generic antifungals such as terbinafine and ketoconazole. Revenue estimates not available, but strategically vital.
  • Generic Products: Sol-Gel produces generic dermatology products. Revenue estimates not available.

Market Dynamics

industry overview logo Industry Overview

The dermatology market is growing, driven by increasing awareness of skin conditions and an aging population. The generic dermatology market is highly competitive with pressures on price and margin.

Positioning

Sol Gel Technologies positions itself as an innovator in the dermatology field, particularly through their microencapsulation technology. Their competitive advantage lies in formulating difficult-to-deliver active ingredients into stable and effective products.

Total Addressable Market (TAM)

The global dermatology market is estimated to be in the tens of billions of dollars. Sol Gel is positioning itself to target key market segments within dermatology

Upturn SWOT Analysis

Strengths

  • Proprietary microencapsulation technology
  • Focus on dermatology
  • Approved products with revenue potential
  • Experienced management team

Weaknesses

  • Limited product portfolio
  • Dependence on key products
  • Relatively small size compared to competitors
  • History of operating losses and dependence on financing

Opportunities

  • Expanding product pipeline
  • Partnering with larger pharmaceutical companies
  • Geographic expansion
  • Potential acquisitions to broaden portfolio

Threats

  • Competition from established dermatology companies
  • Regulatory hurdles
  • Patent expirations
  • Generic competition
  • Unsuccessful clinical trials or regulatory review

Competitors and Market Share

competitor logo Key Competitors

  • VRX
  • PRGO
  • ALNY

Competitive Landscape

Sol Gel Technologies is a smaller player in a highly competitive market. They compete on innovation and specialized dermatology products. Competitor advantages include wider product portfolios and established distribution networks.

Major Acquisitions

No Acquisitions

  • Year: 2024
  • Acquisition Price (USD millions): 0
  • Strategic Rationale: N/A

Growth Trajectory and Initiatives

Historical Growth: Revenue growth has been limited prior to recent product launches. Dependent on key product and market performance.

Future Projections: Analyst estimates are unavailable. Future growth is expected to depend heavily on successful commercialization and product pipeline expansion.

Recent Initiatives: Recent initiatives include the launch of EPSOLAY and ZELSUVMI, focusing on increasing sales and awareness of these products, and further expanding the product portfolio.

Summary

Sol Gel Technologies is a small-cap dermatology company with innovative microencapsulation technology and several approved products. However, it is currently unprofitable and faces intense competition. Success hinges on EPSOLAY and ZELSUVMI's performance, pipeline expansion, and managing its cash burn. There are further catalysts for future expansion and overall growth if operations can continue with revenues balancing spending.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Earnings reports
  • Analyst reports
  • Third Party Financials

Disclaimers:

This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may not be precise. Financial data is based on publicly available information and is subject to change.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Sol Gel Technologies Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2018-01-23
CEO & Executive Chairman Mr. Moshe Arkin
Sector Healthcare
Industry Biotechnology
Full time employees 34
Full time employees 34

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.